Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEH200520 / GEH200521 (18F) PET Imaging in Solid Tumors
NCT05629689Phase 1Terminated
- Sponsor
- GE HealthCare
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEH200520 and GEH200521 in solid tumor (7 arms), sponsored by GE HealthCare. Primary endpoints: Incidence of Adverse Events at 7 days, Severity of Adverse Events at 7 days and 1 more. Started Jan 2023; status: terminated.
02
Drugs
GEH200520GEH200521
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05629689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629689.